ATNT is a biotech company which develops cross-disciplinary engineering methods, to find the most effective molecular targets for treatment of complex human disorders.
Company (Alive / Active)
New Jersey, United States
|Investor||Investor Type||Location||Participating Rounds|
|Boston, Massachusetts, United States||Acquired||Keryx Biopharmaceuticals is working to identify meaningful new medicines to advance the care of people with kidney disease. The company has assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. In September 2014, the U.S. Food and Drug Administration approved Keryx's first medicine, Auryxia (ferric citrate) tablets.||Login to see details|
|Spain||Alive / Active||April 2004, Sensia spun-off from the technologies developed at the Biosensor Group within the National Microelectronics Centre (CNM) of the Spanish National Research Council (CSIC). Concluding research results and availability of biosensing systems already working at lab level originated the proposal of bringing them into commercialisation, after an initial phase of prototyping and industrialisation. This first idea was supported by Genetrix a young biotech company which is interested in devel...Show all||Login to see details|
|Title||Application Date||Patent Date||Status
(Patent / Application)